{
  "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "docSlug": "5062b9a9257606648ea145bccd66e04d",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 40,
  "pageCount": 41,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide highlights the 'OnTarget 2026' initiative, which serves as a strategic milestone for product approval.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/40",
  "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "deckJsonHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json",
  "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-40",
  "components": [
    {
      "bbox": {
        "h": 0.8,
        "w": 0.35,
        "x": 0.62,
        "y": 0.15
      },
      "kind": "callout",
      "text": "OnTarget 2026: MISSION: Bringing new, best-in-class medicines to patients with cancer",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5c38864-91d3-4886-93f7-ee131757a470",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.65,
        "x": 0.08,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "2024: Execute on global registrational strategies; 2025: First pivotal data; 2026: First approved product",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7e82a04-e50e-4f5d-856e-5fe833a3cf2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.5,
        "x": 0.08,
        "y": 0.42
      },
      "kind": "list",
      "text": "Program Status: NVL-520 (ARROS-1 study for ROS1+ NSCLC); NVL-655 (ALKOVE-1 study for ALK+ NSCLC); NVL-330 for HER2+ NSCLC; Additional Discovery Research Programs Ongoing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "711976e3-fdea-44c0-80c7-1022e1c0c0bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "The Path to Patient Impact",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4635777-9ebb-4949-bb5c-6b57e0980283",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "e7eee589-a76a-4c68-a0e6-8d123d9ff956",
      "evidence": "Chronological progression of goals from 2024 to 2026.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}